(295 days)
No
The description focuses on automated quantitative susceptibility testing using a miniaturized doubling dilution technique and monitoring growth over time. There is no mention of AI or ML algorithms being used for analysis or interpretation.
No.
The device is a laboratory aid for determining in vitro susceptibility to antimicrobial agents, not for directly treating a condition.
Yes
The device is described as a "laboratory aid in the determination of in vitro susceptibility to antimicrobial agents," which directly relates to diagnosing the susceptibility of microorganisms to specific drugs.
No
The device description explicitly mentions "VITEK 2 AST Cards" which are physical components, and the system involves automated or manual filling, sealing, and incubation/reading of these cards. While software is used for analysis and reporting, the core functionality relies on hardware and physical consumables.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it is "a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents." This clearly indicates it is used to test samples outside of the body (in vitro) to provide diagnostic information.
- Device Description: The description details how the device tests bacterial isolates in a laboratory setting using a miniaturized microdilution technique. This is a standard method for in vitro diagnostic testing of antimicrobial susceptibility.
- Performance Studies: The performance studies compare the device's performance to a "CLSI broth microdilution reference method," which is a recognized standard for in vitro susceptibility testing.
- Predicate Device: The predicate device listed (VITEK 2 Gram Negative Meropenem) is also an IVD, indicating that this type of device falls under the IVD category.
The device is designed to analyze biological samples (bacterial isolates) in a laboratory setting to provide information about their susceptibility to antimicrobial agents, which is a key characteristic of an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
VITEK® 2 GN Imipenem is designed for antimicrobial susceptibility testing of Gram-negative bacilli. VITEK 2 GN Imipenem is a quantitative test intended for use with the VITEK 2 and VITEK 2 Compact Systems using VITEK 2 Systems 5.02 Software as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. Imipenem has been shown to be active both in vitro and in clinical infections against most strains of the following microorganisms according to the FDA label for the antimicrobial.
Active in vitro and in clinical infections:
Acinetobacter spp.
Citrobacter spp.
Enterobacter aerogenes
Escherichia coli
Klebsiella spp.
Morganella morganii
Proteus vulgaris
Providencia rettgeri
Pseudomonas aeruginosa
Serratia marcescens
Active in vitro but clinical significance unknown: Providencia stuartii
The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 System for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus agalactiae, S. pneumoniae and clinically significant yeast. The VITEK 2 Systems (PC) 5.02 Software is intended for use with VITEK 2 and VITEK 2 Compact Systems.
Product codes
LON
Device Description
VITEK® 2 Gram Negative Imipenem is designed for antimicrobial susceptibility testing of Gram negative microorganisms and is intended for use with the VITEK 2 and VITEK 2 Compact Systems using VITEK 2 Systems (PC) 5.02 software as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK 2 Gram Neqative Imipenem is a quantitative test. Imipenem has been shown to be active against the microorganisms listed below according to the FDA label for the antimicrobial.
The antimicrobial presented in VITEK 2 AST Cards is in concentrations equivalent by efficacy to standard method concentrations in mcg/ml. The VITEK 2 AST Cards are essentially miniaturized versions of the doubling dilution technique for determining the minimum inhibitory concentration (MIC) microdilution methodology. The bacterial isolate to be tested is diluted to a standardized concentration in 0.45 - 0.50% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK 2 System automatically fills, seals and places the card into the incubator/reader. The VITEK 2 Compact has a manual filling and sealing operation. The VITEK 2 monitors the growth of each well in the card over a defined period of time (up to 18 hours). At the completion cycle, a report is generated that contains the MIC value along with the interpretive category result for each antibiotic contained on the card.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
laboratory aid
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
An external evaluation was conducted with fresh clinical isolates and stock challenge strains. The external evaluations were designed to confirm the acceptability of VITEK 2 Gram Negative Imipenem by comparing its performance with the CLSI broth microdilution reference method. The data is representative of performance on both the VITEK 2 Compact instrument platforms.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
VITEK 2 Gram Negative Imipenem demonstrated substantially equivalent performance when compared with the CLSI broth microdilution reference method, as defined in the FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA, Issued August 28, 2009.
VITEK 2 Gram Negative Imipenem using VITEK 2 Systems 5.02 software demonstrated acceptable performance of 95.7% overall Essential Agreement and 94.8% overall Category Agreement. Reproducibility and Quality Control demonstrated acceptable results using both the VITEK 2 and VITEK 2 Compact instrument systems.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Essential Agreement: 95.7% overall
Category Agreement: 94.8% overall
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.1645 Fully automated short-term incubation cycle antimicrobial susceptibility system.
(a)
Identification. A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.(b)
Classification. Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”
0
Image /page/0/Picture/0 description: The image shows the logo for bioMerieux. The logo consists of a circle that is half black and half white with horizontal lines. The text "BIOMERIEUX" is below the circle.
510(k) SUMMARY
VITEK® 2 Gram Negative Imipenem & VITEK 2 Systems (PC) 5.02 Software
510(k) Submission Information:
| Submitter's Name: | bioMérieux, Inc. |
|---|---|
| Address: | 595 Anglum Road |
| Hazelwood, MO 63042 | |
| Contact Person: | Jolyn Tenllado |
| Senior Manager, Regulatory Affairs | |
| Phone Number: | 314-731-8386 |
| Fax Number: | 314-731-8689 |
| Date of Preparation: | December 22, 2010 |
| B. Device Name: | |
| Formal/Trade Name: | VITEK® 2 Gram Negative Imipenem ( $\leq$ 0.25 - $\geq$ 16 µg/ml) |
| Classification Name: | Fully Automated Short-Term Incubation Cycle Antimicrobial |
| Susceptibility Device, 21 CFR 866.1645 | |
| Common Name: | VITEK 2 AST-GN Imipenem |
| C. Predicate Device: | VITEK 2 Gram Negative Meropenem K091899 |
D. 510(k) Summary:
VITEK® 2 Gram Negative Imipenem is designed for antimicrobial susceptibility testing of Gram negative microorganisms and is intended for use with the VITEK 2 and VITEK 2 Compact Systems using VITEK 2 Systems (PC) 5.02 software as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK 2 Gram Neqative Imipenem is a quantitative test. Imipenem has been shown to be active against the microorganisms listed below according to the FDA label for the antimicrobial.
Active in vitro and in clinical infections:
| Acinetobacter spp. | Morganella morganii |
|---|---|
| Citrobacter spp. | Proteus vulgaris |
| Enterobacter aerogenes | Providencia rettgeri |
| Escherichia coli | Pseudomonas aeruginosa |
| Klebsiella spp. | Serratia marcescens |
Active in vitro but clinical significance unknown: Providencia stuartii
The antimicrobial presented in VITEK 2 AST Cards is in concentrations equivalent by efficacy to standard method concentrations in mcg/ml. The VITEK 2 AST Cards are essentially miniaturized versions of the doubling dilution technique for determining the minimum inhibitory concentration (MIC) microdilution methodology.
bioMérieux, Inc.
595 Anglum Road, Hazelwood, Missouri 63042-2320, USA Phone: 314/731-8500 800/6. 8700
1
any 1. 1
The bacterial isolate to be tested is diluted to a standardized concentration in 0.45 - 0 .50% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK 2 System automatically fills, seals and places the card into the incubator/reader. The VITEK 2 Compact has a manual filling and sealing operation. The VITEK 2 monitors the growth of each well in the card over a defined period of time (up to 18 hours). At the completion cycle, a report is generated that contains the MIC value along with the interpretive category result for each antibiotic contained on the card.
VITEK 2 Gram Negative Imipenem demonstrated substantially equivalent performance when compared with the CLSI broth microdilution reference method, as defined in the FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA, Issued August 28, 2009.
The Premarket Notification [510(k)] presents data in support of VITEK 2 Gram Negative Imipenem. An external evaluation was conducted with fresh clinical isolates and stock challenge strains. The external evaluations were designed to confirm the acceptability of VITEK 2 Gram Negative Imipenem by comparing its performance with the CLSI broth microdilution reference method. The data is representative of performance on both the VITEK 2 Compact instrument platforms. VITEK 2 Gram Negative Imipenem using VITEK 2 Systems 5.02 software demonstrated acceptable performance of 95.7% overall Essential Agreement and 94.8% overall Category Agreement. Reproducibility and Quality Control demonstrated acceptable results using both the VITEK 2 and VITEK 2 Compact instrument systems.
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the seal of the U.S. Department of Health and Human Services. The seal is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the top half of the circle. In the center of the seal is a stylized image of an eagle.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993
bioMérieux, Inc. c/o Jolyn Tenllado Director, Regulatory Affairs 595 Anglum Rd. Hazelwood, Missouri 63042
OCT 1 4 2011
Re: K103752
Trade/Device Name: VITEK® 2 Gram Negative Imipenem (=16 µg/mL) with VITEK 2 Systems (PC) 5.02 Software Regulation Number: 21 CFR§ 866.1645 Regulation Name: Short-Term Antimicrobial Susceptibility Test System Regulatory Class: Class II Product Code: LON Dated: October 10, 2011 Received: October 11, 2011
Dear Ms. Tenllado:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter
3
Page 2 – Jolyn Tenllado
will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office
of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Villy a. Htton
Sally A. Hoivat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known): K103752
Device Name: VITEK® 2 Gram Negative Imipenem (=16 µg/mL) with VITEK 2 Systems (PC) 5.02 Software
Indications For Use:
VITEK® 2 GN Imipenem is designed for antimicrobial susceptibility testing of Gram-negative bacilli. VITEK 2 GN Imipenem is a quantitative test intended for use with the VITEK 2 and VITEK 2 Compact Systems using VITEK 2 Systems 5.02 Software as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. Imipenem has been shown to be active both in vitro and in clinical infections against most strains of the following microorganisms according to the FDA label for the antimicrobial.
Active in vitro and in clinical infections:
| Acinetobacter spp. | Morganella morganii |
|---|---|
| Citrobacter spp. | Proteus vulgaris |
| Enterobacter aerogenes | Providencia rettgeri |
| Escherichia coli | Pseudomonas aeruginosa |
| Klebsiella spp. | Serratia marcescens |
Active in vitro but clinical significance unknown: Providencia stuartii
The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 System for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus agalactiae, S. pneumoniae and clinically significant yeast. The VITEK 2 Systems (PC) 5.02 Software is intended for use with VITEK 2 and VITEK 2 Compact Systems.
Prescription Use × (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Freddie M. Poole
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) ki63752